{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:40:21Z","timestamp":1754487621895,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10928-018-9612-y","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T21:17:27Z","timestamp":1542316647000},"page":"15-25","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4790-7975","authenticated-orcid":false,"given":"Yeshitila","family":"Gebremichael","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gezim","family":"Lahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Vakilynejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Melissa","family":"Hallow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"issue":"5","key":"9612_CR1","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1440-1681.1981.tb00745.x","volume":"8","author":"BJ Morris","year":"1981","unstructured":"Morris BJ, Catanzaro DF (1981) Biosynthesis of preprorenin and intracellular conversion of prorenin to renin. Clin Exp Pharmacol Physiol 8(5):441\u2013445","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"5","key":"9612_CR2","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1161\/HYPERTENSIONAHA.108.110924","volume":"51","author":"DJ Campbell","year":"2008","unstructured":"Campbell DJ (2008) Critical review of prorenin and (pro)renin receptor research. Hypertension 51(5):1259\u20131264. \n                    https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.110924","journal-title":"Hypertension"},{"key":"9612_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/112_2015_27","volume":"169","author":"JP Mochel","year":"2015","unstructured":"Mochel JP, Danhof M (2015) Chronobiology and pharmacologic modulation of the renin-angiotensin-aldosterone system in dogs: what have we learned? Rev Physiol Biochem Pharmacol 169:43\u201369. \n                    https:\/\/doi.org\/10.1007\/112_2015_27","journal-title":"Rev Physiol Biochem Pharmacol"},{"issue":"Suppl 5","key":"9612_CR4","first-page":"S19","volume":"9","author":"F Fyhrquist","year":"1995","unstructured":"Fyhrquist F, Metsarinne K, Tikkanen I (1995) Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens 9(Suppl 5):S19\u2013S24","journal-title":"J Hum Hypertens"},{"issue":"1","key":"9612_CR5","doi-asserted-by":"publisher","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","volume":"292","author":"PK Mehta","year":"2007","unstructured":"Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292(1):C82\u2013C97. \n                    https:\/\/doi.org\/10.1152\/ajpcell.00287.2006","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"9612_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/FJC.0000000000000208","volume":"65","author":"LC Matavelli","year":"2015","unstructured":"Matavelli LC, Siragy HM (2015) AT2 receptor activities and pathophysiological implications. J Cardiovasc Pharmacol 65(3):226\u2013232. \n                    https:\/\/doi.org\/10.1097\/fjc.0000000000000208","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"9612_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/MNH.0000000000000289","volume":"26","author":"AA Peluso","year":"2017","unstructured":"Peluso AA, Santos RA, Unger T, Steckelings UM (2017) The angiotensin type 2 receptor and the kidney. Curr Opin Nephrol Hypertens 26(1):36\u201342. \n                    https:\/\/doi.org\/10.1097\/mnh.0000000000000289","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"9612_CR8","doi-asserted-by":"publisher","DOI":"10.4172\/jcs.1000111","author":"KD Singh","year":"2016","unstructured":"Singh KD, Karnik SS (2016) Angiotensin receptors: structure, function, signaling and clinical applications. J Cell Signal. \n                    https:\/\/doi.org\/10.4172\/jcs.1000111","journal-title":"J Cell Signal"},{"issue":"6","key":"9612_CR9","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","volume":"160","author":"TK Ma","year":"2010","unstructured":"Ma TK, Kam KK, Yan BP, Lam YY (2010) Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 160(6):1273\u20131292. \n                    https:\/\/doi.org\/10.1111\/j.1476-5381.2010.00750.x","journal-title":"Br J Pharmacol"},{"issue":"4","key":"9612_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.amjmed.2007.11.016","volume":"121","author":"MM Shafiq","year":"2008","unstructured":"Shafiq MM, Menon DV, Victor RG (2008) Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug. Am J Med 121(4):265\u2013271. \n                    https:\/\/doi.org\/10.1016\/j.amjmed.2007.11.016","journal-title":"Am J Med"},{"issue":"5","key":"9612_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.amjhyper.2007.04.001","volume":"20","author":"JE Sealey","year":"2007","unstructured":"Sealey JE, Laragh JH (2007) Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 20(5):587\u2013597. \n                    https:\/\/doi.org\/10.1016\/j.amjhyper.2007.04.001","journal-title":"Am J Hypertens"},{"issue":"1","key":"9612_CR12","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/hy0102.102293","volume":"39","author":"J Nussberger","year":"2002","unstructured":"Nussberger J, Wuerzner G, Jensen C, Brunner HR (2002) Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39(1):E1\u2013E8","journal-title":"Hypertension"},{"issue":"6","key":"9612_CR13","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","volume":"42","author":"A Stanton","year":"2003","unstructured":"Stanton A, Jensen C, Nussberger J, O\u2019Brien E (2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42(6):1137\u20131143. \n                    https:\/\/doi.org\/10.1161\/01.hyp.0000101688.17370.87","journal-title":"Hypertension"},{"issue":"10","key":"9612_CR14","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1021\/acsmedchemlett.6b00251","volume":"7","author":"Y Imaeda","year":"2016","unstructured":"Imaeda Y, Tokuhara H, Fukase Y, Kanagawa R, Kajimoto Y, Kusumoto K, Kondo M, Snell G, Behnke CA, Kuroita T (2016) Discovery of TAK-272: a novel, potent, and orally active renin inhibitor. ACS Med Chem Lett 7(10):933\u2013938. \n                    https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00251","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"9612_CR15","doi-asserted-by":"publisher","first-page":"H137","DOI":"10.1152\/ajpheart.00618.2015","volume":"310","author":"MC Chappell","year":"2016","unstructured":"Chappell MC (2016) Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol 310(2):H137\u2013H152. \n                    https:\/\/doi.org\/10.1152\/ajpheart.00618.2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"9612_CR16","volume-title":"Clinical trial simulations","author":"A Lo","year":"2011","unstructured":"Lo A, Beh J, de Leon H, Hallow KM, Ramakrishna R, Rodrigo M, Sarkar A, Sarangapani R, Georgieva A (2011) Using a systems biology approach to explore hypotheses underlying clinical diversity of the renin angiotensin system and the response to antihypertensive therapies. In: Kimko HC, Peck C (eds) Clinical trial simulations. Springer, New York"},{"issue":"9","key":"9612_CR17","doi-asserted-by":"publisher","first-page":"R647","DOI":"10.1152\/ajpregu.00039.2013","volume":"306","author":"KM Hallow","year":"2014","unstructured":"Hallow KM, Lo A, Beh J, Rodrigo M, Ermakov S, Friedman S, de Leon H, Sarkar A, Xiong Y, Sarangapani R, Schmidt H, Webb R, Kondic AG (2014) A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model. Am J Physiol Regul Integr Comp Physiol 306(9):R647\u2013R662. \n                    https:\/\/doi.org\/10.1152\/ajpregu.00039.2013","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"6","key":"9612_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/psp4.12178","volume":"6","author":"KM Hallow","year":"2017","unstructured":"Hallow KM, Gebremichael Y (2017) A quantitative systems physiology model of renal function and blood pressure regulation: model description. CPT Pharmacometri Syst Pharmacol 6(6):383\u2013392. \n                    https:\/\/doi.org\/10.1002\/psp4.12178","journal-title":"CPT Pharmacometri Syst Pharmacol"},{"issue":"1","key":"9612_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/sj.clpt.6100495","volume":"84","author":"Y Hong","year":"2008","unstructured":"Hong Y, Dingemanse J, Mager DE (2008) Pharmacokinetic\/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren. Clin Pharmacol Ther 84(1):136\u2013143. \n                    https:\/\/doi.org\/10.1038\/sj.clpt.6100495","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"9612_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/psp4.12177","volume":"6","author":"KM Hallow","year":"2017","unstructured":"Hallow KM, Gebremichael Y (2017) A quantitative systems physiology model of renal function and blood pressure regulation: application in salt-sensitive hypertension. CPT Pharmacometr Syst Pharmacol 6(6):393\u2013400. \n                    https:\/\/doi.org\/10.1002\/psp4.12177","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"5","key":"9612_CR21","doi-asserted-by":"publisher","first-page":"F819","DOI":"10.1152\/ajprenal.00497.2016","volume":"312","author":"KM Hallow","year":"2017","unstructured":"Hallow KM, Gebremichael Y, Helmlinger G, Vallon V (2017) Primary proximal tubule hyperreabsorption and impaired tubular transport counterregulation determine glomerular hyperfiltration in diabetes: a modeling analysis. Am J Physiol Renal Physiol 312(5):F819\u2013F835. \n                    https:\/\/doi.org\/10.1152\/ajprenal.00497.2016","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"9612_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/psp4.12052","volume":"5","author":"W Wang","year":"2016","unstructured":"Wang W, Hallow KM, James DA (2016) A tutorial on RxODE: simulating differential equation pharmacometric models in R. CPT Pharmacometr Syst Pharmacol 5(1):3\u201310. \n                    https:\/\/doi.org\/10.1002\/psp4.12052","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"4","key":"9612_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3109\/07420528509055889","volume":"2","author":"P Cugini","year":"1985","unstructured":"Cugini P, Murano G, Lucia P, Letizia C, Scavo D, Halberg F, Cornelissen G, Sothern RB (1985) Circadian rhythms of plasma renin activity and aldosterone: changes related to age, sex, recumbency and sodium restriction. Chronobiologic specification for reference values. Chronobiol Int 2(4):267\u2013276","journal-title":"Chronobiol Int"},{"issue":"4","key":"9612_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/ajh.2009.260","volume":"23","author":"RC Hermida","year":"2010","unstructured":"Hermida RC, Ayala DE, Mojon A, Fernandez JR (2010) Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of subjects with resistant hypertension. Am J Hypertens 23(4):432\u2013439. \n                    https:\/\/doi.org\/10.1038\/ajh.2009.260","journal-title":"Am J Hypertens"},{"issue":"5","key":"9612_CR25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3109\/07420528.2014.897711","volume":"31","author":"JP Mochel","year":"2014","unstructured":"Mochel JP, Fink M, Bon C, Peyrou M, Bieth B, Desevaux C, Deurinck M, Giraudel JM, Danhof M (2014) Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs. Chronobiol Int 31(5):715\u2013730. \n                    https:\/\/doi.org\/10.3109\/07420528.2014.897711","journal-title":"Chronobiol Int"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-018-9612-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9612-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-018-9612-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T19:45:14Z","timestamp":1573847114000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-018-9612-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["9612"],"URL":"https:\/\/doi.org\/10.1007\/s10928-018-9612-y","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"type":"print","value":"1567-567X"},{"type":"electronic","value":"1573-8744"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"assertion":[{"value":"9 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G. Lahu and M. Vakilynejad are\/were employees of Takeda Pharmaceutical Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}